Previous close | 48.05 |
Open | 50.20 |
Bid | 42.40 |
Ask | 46.30 |
Strike | 185.00 |
Expiry date | 2024-09-20 |
Day's range | 48.05 - 50.20 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Moody's released a new report Tuesday that reins in Wall Street expectations for the impact of GLP-1s on other industries.
As global markets continue to navigate a landscape marked by political uncertainties and varying economic signals, investors are keenly observing trends that could hint at potential opportunities. In such an environment, identifying stocks that appear undervalued becomes crucial, offering a strategic avenue for those looking to potentially enhance their portfolios amidst ongoing volatility.
Weight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American Diabetes Association are increasingly dominated by news on obesity drugs.